Monitor Phase 2 MoMeNtum data in MMN (Q4'26) and CAPTIVATE Part B update (YE'26) as nearer-term catalysts; Phase 3 gMG data (2H'28) is too distant to drive near-term price action. Insider selling ahead of this announcement may signal limited upside in the near term.
Price Chart
Executive Summary
Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on positive Phase 2 results. Top-line data expected in 2H'28; the stock may see modest positive momentum from trial advancement but major catalysts are distant.
Key Facts
- Phase 3 EMERGE trial initiated in ~195 AChR+ gMG patients with claseprubart 300mg Q2W or Q4W
- Primary endpoint: change from baseline in MG-ADL; top-line results expected 2H'28
- Claseprubart granted Orphan Drug Designation by FDA for MG in May 2026
- Phase 2 MaGic trial showed rapid, sustained, statistically significant improvements vs placebo
- Additional catalysts: MMN Phase 2 data Q4'26, CIDP Phase 3 Part B timing update by YE'26
Financial Impact
No direct revenue impact; pipeline progression supports valuation but revenues years away
Risk Factors
- Clinical trial failure or disappointing efficacy/safety
- Competition from existing and emerging gMG therapies
- Dilution risk if additional capital is needed before data readouts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318826 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access